Want to see NTRA full AI Analyst Report?
NTRA Stock Chart & Stats
$208.40
$1.33(0.78%)
At close: 4:00 PM EST
$208.40
$1.33(0.78%)
Day’s Range― - ―
52-Week Range$131.81 - $288.04
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.59M
Market Cap
$40.37B
Enterprise Value$31.58B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$240.08M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Jul 30, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding143,215,380
10 Day Avg. Volume1,617,852
30 Day Avg. Volume1,585,694
Financial Highlights & Ratios
PEG Ratio230.60
Price to Book (P/B)18.29
Price to Sales (P/S)13.58
P/FCF Ratio287.05
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue12.63
Enterprise Value/Gross Profit19.38
Enterprise Value/Ebitda-141.14
Forecast
1Y Price Target
$274.00Price Target Upside31.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$2.80B
Bulls Say, Bears Say
Bulls Say
Improved Cash Generation And Low LeverageMaterial positive operating and free cash flow alongside low leverage provides durable financial flexibility. Positive OCF and FCF reduce reliance on external capital, support ongoing R&D and commercialization, and lower refinancing risk as the company scales over the next 2–6 months.
Scale, ASP Improvement And Sustainable Gross MarginsRapid volume scale plus rising ASPs and a ~65% gross margin indicate strong unit economics and operating leverage. Sustained high margins with expanding volumes support durable margin sustainability and cash generation if reimbursement and pricing trends persist.
Regulatory Clearance Expands European Market AccessIVDR Class C certification is a structural win that secures EU market access and reduces regulatory friction for trials and launches. This durable regulatory clearance supports long‑term TAM expansion and commercial rollout in Europe beyond 2028.
Bears Say
Ongoing Losses And Negative ReturnsDespite improving scale and cash flow, the company still reports net losses and negative ROE. Persistent unprofitability limits retained earnings accumulation and could force continued reliance on external capital or slower deleveraging if margins don't convert to sustained net income.
Reimbursement And Coverage UncertaintyIncomplete Medicare/commercial coverage and prior authorization frictions are structural adoption constraints. Even with strong clinical data, prolonged reimbursement uncertainty can cap utilization, limit pricing power, and delay realization of scale economics across tumor types.
Potential Shareholder Dilution From Equity Plan ExpansionAn enlarged equity award pool signals ongoing reliance on stock incentives to retain talent during growth. Over time, additional share issuance can dilute existing holders and pressure per‑share metrics, a structural governance and capital‑allocation consideration as investments continue.
NTRA FAQ
What was Natera Inc.’s price range in the past 12 months?
Natera Inc. lowest stock price was $131.81 and its highest was $288.04 in the past 12 months.
What is Natera Inc.’s market cap?
Natera Inc.’s market cap is $40.37B.
When is Natera Inc.’s upcoming earnings report date?
Natera Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Natera Inc.’s earnings last quarter?
Natera Inc. released its earnings results on May 07, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.542 by -$0.058.
Is Natera Inc. overvalued?
According to Wall Street analysts Natera Inc.’s price is currently Undervalued.
Does Natera Inc. pay dividends?
Natera Inc. does not currently pay dividends.
What is Natera Inc.’s EPS estimate?
Natera Inc.’s EPS estimate is -0.49.
How many shares outstanding does Natera Inc. have?
Natera Inc. has 143,215,380 shares outstanding.
What happened to Natera Inc.’s price movement after its last earnings report?
Natera Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.542. Following the earnings report the stock price went down -11.637%.
Which hedge fund is a major shareholder of Natera Inc.?
Currently, no hedge funds are holding shares in NTRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$274.00 (31.48% Upside)
$274.00 (31.48% Upside)
Blogger Sentiment
Bullish
NTRA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 450.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 21.9%
Last 30 Days ▲ 21.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.24%
12-Months-Change
Fundamentals
Return on Equity
-15.13%
Trailing 12-Months
Asset Growth
50.91%
Trailing 12-Months
Company Description
Natera Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
NTRA Company Deck
NTRA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based operational momentum—robust revenue and unit growth (Q1 revenue $697M, +39% YoY), record oncology volumes (249k MRD tests, +55% YoY), successful new-product launches (Fetal Focus approaching ~200k annualized orders), improved ASPs (Signatera ~$1,250) and raised guidance (revenue guide midpoint reset up >$120M; gross margin guidance to 65% midpoint). Transient headwinds (work-in-process timing, acquisition-related COGS, temporary DSO impact, weather effects, and some coverage/authorization friction) were identified but characterized as short-term or manageable. Given the magnitude and number of positive operational and financial developments and management's upward guide and investment posture, the highlights materially outweigh the lowlights.View all NTRA earnings summariesNTRA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$274.00
▲(31.48% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
3.05% Insiders
34.30% Mutual Funds
0.40% Other Institutional Investors
46.33% Public Companies and
Individual Investors








